Sugi Predict

Sugi Predict / Compounds / SCHEMBL838534

SCHEMBL838534

SCHEMBL838534

N#Cc1ccc(C[C@@H](N)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.62
▸ PTGS1 P23219 3/20 0.61
▸ ALPI P09923 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ XIAP P98170 1/20 0.61
▸ TPH1 P17752 2/20 0.58
▸ HIF1A Q16665 4/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ FYN P06241 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ GRB2 P62993 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43594 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL43593 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL1183792 0.98 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL10420165 0.98 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL9710930 0.98 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL14601776 0.95 TPH1 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17060769 0.95 TPH1 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL23077761 0.92 SLC7A5 (0.54) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL10266644 0.86 DPP4 (0.52) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8650928 0.86 DPP4 (0.52) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119487044-A Novel mercaptan reducing agent and preparation method and application thereof 苏州佰睿壹生物技术有限公司 2025-02-18 — — CN claimed
CN-119365471-A Novel thiol reducing agents, methods and uses thereof 苏州佰睿壹生物技术有限公司 2025-01-24 — — CN claimed
US-12187816-B2 Macrocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2025-01-07 — — US claimed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 — — EP claimed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 — — WO claimed
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 — — US disclosed
EP-4673162-A1 PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) 2026-01-07 — — EP disclosed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250320310-A1 A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) 2025-10-16 — — US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
US-20030022821-A1 Bioactive peptides ALPHARMA AS 2003-01-30 — — US disclosed
EP-1109831-A2 CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2001-06-27 — — EP disclosed
EP-1109827-A2 BIOACTIVE PEPTIDES ALPHARMA AS (NO) 2001-06-27 — — EP disclosed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 — — EP disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed
WO-2000012541-A2 CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 — — WO disclosed
WO-1996005189-A1 INHIBITORS OF THE BENZAMIDINE TYPE PENTAPHARM AG (CH) 1996-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT SLC7A5 921/4885PTGS1 3983/4885ALPI 4083/4885
US-12187816-B2 Macrocyclic compounds and methods of use thereof PAICS, CYCS, LSS SLC7A5 1506/4885PTGS1 2992/4885ALPI 678/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 SLC7A5 1405/4885PTGS1 1907/4885ALPI 563/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B SLC7A5 1050/4885PTGS1 2516/4885ALPI 818/4885
US-20250320310-A1 A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION PTMS, PDIA6, SCLY SLC7A5 4317/4885PTGS1 4611/4885ALPI 4197/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 SLC7A5 1741/4885PTGS1 3808/4885ALPI 2844/4885
US-20030022821-A1 Bioactive peptides VIP, LITAF, LNPEP SLC7A5 111/4885PTGS1 3546/4885ALPI 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.